After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...